CY1109437T1 - ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ - Google Patents

ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ

Info

Publication number
CY1109437T1
CY1109437T1 CY20091100108T CY091100108T CY1109437T1 CY 1109437 T1 CY1109437 T1 CY 1109437T1 CY 20091100108 T CY20091100108 T CY 20091100108T CY 091100108 T CY091100108 T CY 091100108T CY 1109437 T1 CY1109437 T1 CY 1109437T1
Authority
CY
Cyprus
Prior art keywords
compositions
glycanes
specific significance
specific
kits
Prior art date
Application number
CY20091100108T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Ibrahim Fattom
Robert B Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of CY1109437T1 publication Critical patent/CY1109437T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Αποκαλύπτονται συνθέσεις και τυποποιημένες συσκευασίες που περιέχουν συνδυασμούς βήτα-γλυκανών και ειδικών ανοσοσφαιρινών. Οι συνθέσεις και οι τυποποιημένες συσκευασίες είναι χρήσιμες για μεθόδους πρόληψης ή θεραπείας μόλυνσης από έναν παθογόνο μικροργανισμό, στις οποίες χορηγείται β-γλυκάνη σε ένα άτομο και εισάγονται ειδικά αντισώματα έναντι του παθογόνου μικροργανισμού στο άτομο αυτό.
CY20091100108T 1998-09-14 2009-01-29 ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ CY1109437T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14
EP99969030A EP1121135B1 (en) 1998-09-14 1999-09-14 Compositions of beta-glucans and specific immunoglobulins

Publications (1)

Publication Number Publication Date
CY1109437T1 true CY1109437T1 (el) 2014-08-13

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100108T CY1109437T1 (el) 1998-09-14 2009-01-29 ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ

Country Status (11)

Country Link
US (1) US6355625B1 (el)
EP (1) EP1121135B1 (el)
AT (1) ATE421883T1 (el)
AU (1) AU6033299A (el)
CA (1) CA2344166C (el)
CY (1) CY1109437T1 (el)
DE (1) DE69940371D1 (el)
DK (1) DK1121135T3 (el)
ES (1) ES2321892T3 (el)
PT (1) PT1121135E (el)
WO (1) WO2000015238A1 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1357919B1 (en) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
WO2006085895A2 (en) * 2004-05-10 2006-08-17 Biopolymer Engineering, Inc. Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
JP5296531B2 (ja) * 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
NZ565069A (en) 2005-06-13 2011-08-26 Glaxosmithkline Biolog Sa Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
KR20090019007A (ko) 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
MX364642B (es) 2010-05-05 2019-05-03 Univ New York Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9091689B2 (en) 2011-06-19 2015-07-28 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
ES2609817T3 (es) 2011-06-19 2017-04-24 New York University Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
WO2013025834A2 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
BR112014026861A2 (pt) 2012-04-26 2018-05-15 Univ Chicago antígenos de estafilococos coagulase e métodos de seu uso
KR20150013206A (ko) * 2012-04-30 2015-02-04 바이오테라, 인크. β-글루칸 면역요법을 위한 조성물 및 방법
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
US11214600B2 (en) 2016-02-12 2022-01-04 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
AU6033299A (en) 2000-04-03
ES2321892T3 (es) 2009-06-12
EP1121135A1 (en) 2001-08-08
DK1121135T3 (da) 2009-03-23
WO2000015238B1 (en) 2000-08-31
EP1121135A4 (en) 2005-03-16
EP1121135B1 (en) 2009-01-28
CA2344166C (en) 2008-11-18
ATE421883T1 (de) 2009-02-15
WO2000015238A9 (en) 2000-10-12
WO2000015238A1 (en) 2000-03-23
US6355625B1 (en) 2002-03-12
CA2344166A1 (en) 2000-03-23
PT1121135E (pt) 2009-03-05
DE69940371D1 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
DE60026691D1 (de) Staphylococcus-antigene und impstoff
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0014470A (pt) Inibidores de fab i
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
DE69420967D1 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
EA200000196A1 (ru) Универсальная плазма крови
DK312688A (da) Glykkopeptid-antibiotika
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
EA200100700A1 (ru) Гены и белки и их применение
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
ITMI950378A0 (it) Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
TR199800897T2 (xx) Siklopeptolidler
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.